 | Date of last change: 09 March 2009 Type of document: Presentation; Pages: 100; Time allotted: 75 min Description: Epidemiology and clinical features of human infection with influenza A (H5N1) virus; clinical assessment, epidemiologic assessment, diagnosis, and treatment of suspected influenza A (H5N1) patients | |
 | Date of last change: 09 March 2009 Type of document: Presentation; Pages: 60; Time allotted: 100 min Description: This case study addressed responding to an influenza outbreak in an international setting. | |
 | Date of last change: 09 March 2009 Type of document: Training Guide; Pages: 38; Time allotted: 60 min Description: This case study addressed how to enchance surveillance, and building pandemic early warning systems. | |
 | Type of document: Training Guide; Pages: 29; Time allotted: 60 min Description: Facilitator's guide Abstract: Outbreak | |
 | Date of last change: 09 March 2009 Type of document: Training Guide; Pages: 21; Time allotted: 60 min Description: Facilitator's guide | |
 | Date of last change: 09 March 2009 Type of document: Presentation; Pages: 55; Time allotted: 45 min Description: Seasonal and pandemic influenza vaccines; covers development and production, safety and effectiveness | |
 | Date of last change: 01 March 2007 Type of document: Guideline; Pages: 8; Time allotted: N.A. Description: Recommendations for laboratories receiving requests to test for specimen from patients with an influenza-like illness Abstract: Initial laboratory testing of each specimen should be to diagnose influenza A virus infection rapidly and exclude other common viral respiratory infections. The recommendations for procedures include: rapid antigen detection, virus culture, and polymerase chain reaction and Real-time PCR assays. Specimen with positive result should be further tested and verified by a designated WHO H5 Reference laboratory. | |
 | Date of last change: 2004 Type of document: Guideline; Pages: 25; Time allotted: N.A. Description: Recommendations for monitoring spread of influenza Abstract: The WHO recommends enhanced surveillance for influenza A/H5 to ensure close global monitoring of the situation and coordination of the global response. As the epidemiological situation evolves, WHO will review these guidelines. | |